Compare Stocks

Date Range: 

 Sangamo TherapeuticsKrystal BiotechKymera TherapeuticsImmunovantAlector
SymbolNASDAQ:SGMONASDAQ:KRYSNASDAQ:KYMRNASDAQ:IMVTNASDAQ:ALEC
Price Information
Current Price$10.39$71.86$41.24$16.40$15.71
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.31.51.11.61.3
Analysis Score3.43.52.43.53.5
Community Score2.52.51.73.72.4
Dividend Score0.00.00.00.00.0
Ownership Score0.81.70.80.80.8
Earnings & Valuation Score0.00.00.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$20.50$101.00$48.67$45.60$34.40
% Upside from Price Target97.31% upside40.55% upside18.01% upside178.05% upside118.97% upside
Trade Information
Market Cap$1.63 billion$1.60 billion$1.87 billion$1.59 billion$1.25 billion
Beta1.971.2N/AN/A1.08
Average Volume1,424,825140,556327,4001,314,898624,187
Sales & Book Value
Annual Revenue$102.43 millionN/AN/AN/A$21.22 million
Price / Sales14.58N/AN/AN/A59.05
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$3.73 per share$11.72 per shareN/A$1.45 per share$2.83 per share
Price / Book2.79N/AN/AN/A5.55
Profitability
Net Income$-95,190,000.00$-19,090,000.00N/A$-66,390,000.00$-105,390,000.00
EPS($0.85)($1.20)N/A($1.54)($1.71)
Trailing P/E RatioN/AN/A0.00N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-51.51%N/AN/AN/A-757.78%
Return on Equity (ROE)-16.32%-10.72%N/A-34.80%-53.86%
Return on Assets (ROA)-9.85%-10.40%N/A-32.38%-31.44%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio5.67%39.96%N/A35.15%6.61%
Quick Ratio5.67%39.96%N/A35.15%6.61%
Ownership Information
Institutional Ownership Percentage57.69%73.05%37.83%40.21%61.50%
Insider Ownership Percentage1.80%27.40%N/A0.24%13.90%
Miscellaneous
Employees413757542171
Shares Outstanding143.71 million22.20 million45.07 million97.97 million79.76 million
Next Earnings Date8/4/2021 (Estimated)N/A6/10/2021 (Estimated)7/5/2021 (Estimated)5/12/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans - Yahoo FinanceAlector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
finance.yahoo.com - May 5 at 1:50 PM
Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth PlansAlector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - May 5 at 1:50 PM
Alector (NASDAQ:ALEC)  Shares Down 5.3% Alector (NASDAQ:ALEC) Shares Down 5.3%
americanbankingnews.com - May 5 at 1:15 PM
Alector, Inc. (NASDAQ:ALEC)’s 3.94% Gain This Week Just Tells Us Something NewAlector, Inc. (NASDAQ:ALEC)’s 3.94% Gain This Week Just Tells Us Something New
marketingsentinel.com - May 1 at 2:20 PM
Alector (NASDAQ:ALEC) Downgraded by Zacks Investment ResearchAlector (NASDAQ:ALEC) Downgraded by Zacks Investment Research
marketbeat.com - April 28 at 4:19 PM
Alzheimers Disease Diagnostic Market In-Depth Analysis Of Competitive Landscape Executive Summary Development Factors 2028 – Valley Bugler Newspaper - Valley Bugler NewspaperAlzheimer's Disease Diagnostic Market In-Depth Analysis Of Competitive Landscape Executive Summary Development Factors 2028 – Valley Bugler Newspaper - Valley Bugler Newspaper
valleybugler.com - April 28 at 8:53 AM
Global Online Medical Market To Accelerate Growth Point to Healthy Revenue Trajectory in Coming Year 2020-2026 – By Global Marketers - Clark County BlogGlobal Online Medical Market To Accelerate Growth Point to Healthy Revenue Trajectory in Coming Year 2020-2026 – By Global Marketers - Clark County Blog
clarkcountyblog.com - April 28 at 3:52 AM
Alzheimers Disease Diagnostic Market 2021 Analysis By Regional, Outlook, Competitive Landscape Str - PharmiWeb.comAlzheimer's Disease Diagnostic Market 2021 Analysis By Regional, Outlook, Competitive Landscape Str - PharmiWeb.com
pharmiweb.com - April 27 at 12:19 PM
Morgan Stanley Raises Alector (NASDAQ:ALEC) Price Target to $33.00Morgan Stanley Raises Alector (NASDAQ:ALEC) Price Target to $33.00
americanbankingnews.com - April 26 at 9:32 AM
Alector (NASDAQ:ALEC) Price Target Increased to $33.00 by Analysts at Morgan StanleyAlector (NASDAQ:ALEC) Price Target Increased to $33.00 by Analysts at Morgan Stanley
americanbankingnews.com - April 26 at 9:32 AM
Alzheimers Disease Drugs and Diagnostics Market Production, Revenue and Price Forecast by Type 2021 to 2027 – GE Healthcare, TauRx, Eisai Co. Ltd, Biogen Inc., Neuro-Bio Ltd, Cognition Therapeutics Inc., Eli Lilly and Company, Novartis AG, Accera, Alector LLC, Treventis Corporation - Clark County BlogAlzheimer's Disease Drugs and Diagnostics Market Production, Revenue and Price Forecast by Type 2021 to 2027 – GE Healthcare, TauRx, Eisai Co. Ltd, Biogen Inc., Neuro-Bio Ltd, Cognition Therapeutics Inc., Eli Lilly and Company, Novartis AG, Accera, Alector LLC, Treventis Corporation - Clark County Blog
clarkcountyblog.com - April 26 at 7:46 AM
Alzheimers Disease Drugs and Diagnostics Market Production, Revenue and Price Forecast by Type 2021 to 2027 – GE Healthcare, TauRx, Eisai Co. Ltd, Biogen Inc., Neuro-Bio Ltd, Cognition Therapeutics Inc., Eli Lilly and Company, Novartis AG, Accera, Alector LLC, Treventis Corporation - Clark County BlogAlzheimer's Disease Drugs and Diagnostics Market Production, Revenue and Price Forecast by Type 2021 to 2027 – GE Healthcare, TauRx, Eisai Co. Ltd, Biogen Inc., Neuro-Bio Ltd, Cognition Therapeutics Inc., Eli Lilly and Company, Novartis AG, Accera, Alector LLC, Treventis Corporation - Clark County Blog
clarkcountyblog.com - April 26 at 7:46 AM
Neurodegenerative Diseases Industry Market to Eyewitness Massive Growth by 2028: Biogen Idec, Alector, Bayer. – Clark County Blog - Clark County BlogNeurodegenerative Diseases Industry Market to Eyewitness Massive Growth by 2028: Biogen Idec, Alector, Bayer. – Clark County Blog - Clark County Blog
clarkcountyblog.com - April 24 at 8:00 AM
Alector (NASDAQ:ALEC) Trading Down 3.3%Alector (NASDAQ:ALEC) Trading Down 3.3%
americanbankingnews.com - April 21 at 2:02 PM
Frontotemporal Dementia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | TauRx Therapeutics, Alector, Neurimmune, Biogen and Others. - Virtual-Strategy MagazineFrontotemporal Dementia Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | TauRx Therapeutics, Alector, Neurimmune, Biogen and Others. - Virtual-Strategy Magazine
virtual-strategy.com - April 19 at 10:22 PM
Alector (NASDAQ:ALEC) PT Raised to $33.00Alector (NASDAQ:ALEC) PT Raised to $33.00
americanbankingnews.com - April 19 at 10:28 AM
2021 Latest Report on: Alzheimer S Disease Diagnostic Market Size, Demand Status | Global Industry Segment Analysis, Growing Status of Key Players| Eli Lilly, TauRx, Alector, Accera - Los Hijos de la Malinche2021 Latest Report on: Alzheimer S Disease Diagnostic Market Size, Demand Status | Global Industry Segment Analysis, Growing Status of Key Players| Eli Lilly, TauRx, Alector, Accera - Los Hijos de la Malinche
loshijosdelamalinche.com - April 17 at 7:39 AM
Alector (NASDAQ:ALEC) Trading 6.5% Higher Alector (NASDAQ:ALEC) Trading 6.5% Higher
americanbankingnews.com - April 15 at 12:50 PM
Is Alector Inc (ALEC) a Stock to Watch After Losing -14.60% This Week? - InvestorsObserverIs Alector Inc (ALEC) a Stock to Watch After Losing -14.60% This Week? - InvestorsObserver
investorsobserver.com - April 9 at 5:47 PM
Stocks Mixed at Midday, Still on Track for Solid Weekly Gains - Schaeffers ResearchStocks Mixed at Midday, Still on Track for Solid Weekly Gains - Schaeffers Research
schaeffersresearch.com - April 9 at 12:47 PM
Numenor Capital Portfolio Update #1 - Seeking AlphaNumenor Capital Portfolio Update #1 - Seeking Alpha
seekingalpha.com - April 6 at 2:32 PM
Do Analysts Expect Alector Inc (ALEC) Stock to Rise After It Has Risen 13.77% in a Month? - InvestorsObserverDo Analysts Expect Alector Inc (ALEC) Stock to Rise After It Has Risen 13.77% in a Month? - InvestorsObserver
investorsobserver.com - March 31 at 7:48 PM
Replay: Investing in Alzheimer’s Treatment — Jupiter Orphan Therapeutics CEO Joins Fireside ChatReplay: Investing in Alzheimer’s Treatment — Jupiter Orphan Therapeutics CEO Joins Fireside Chat
finance.yahoo.com - March 30 at 1:32 PM
Check this Alector, Inc. (NASDAQ:ALEC) Analysis Before You InvestCheck this Alector, Inc. (NASDAQ:ALEC) Analysis Before You Invest
stocksregister.com - March 27 at 9:49 AM
Alector to Present at Stifel’s 3rd Annual CNS Day - Yahoo FinanceAlector to Present at Stifel’s 3rd Annual CNS Day - Yahoo Finance
finance.yahoo.com - March 26 at 6:47 PM
Alector to Present at Stifels 3rd Annual CNS Day - GlobeNewswireAlector to Present at Stifel's 3rd Annual CNS Day - GlobeNewswire
globenewswire.com - March 25 at 10:44 PM
DateCompanyBrokerageAction
5/3/2021Sangamo TherapeuticsRoyal Bank of CanadaInitiated Coverage
3/3/2021Sangamo TherapeuticsWells Fargo & CompanyLower Price Target
1/5/2021Sangamo TherapeuticsStifel NicolausInitiated Coverage
12/16/2020Sangamo TherapeuticsHC WainwrightReiterated Rating
9/8/2020Sangamo TherapeuticsBank of AmericaInitiated Coverage
7/7/2020Sangamo TherapeuticsSunTrust BanksInitiated Coverage
6/19/2020Sangamo TherapeuticsWedbushReiterated Rating
12/9/2019Sangamo TherapeuticsCowenReiterated Rating
11/14/2018Sangamo TherapeuticsJPMorgan Chase & Co.Downgrade
11/9/2018Sangamo TherapeuticsGuggenheimDowngrade
2/9/2021Krystal BiotechJonestradingInitiated Coverage
11/11/2020Krystal BiotechB. RileyReiterated Rating
8/25/2020Krystal BiotechChardan CapitalReiterated Rating
6/4/2020Krystal BiotechEvercore ISIInitiated Coverage
5/4/2020Krystal BiotechWilliam BlairReiterated Rating
9/24/2019Krystal BiotechThe Goldman Sachs GroupInitiated Coverage
4/20/2021Kymera TherapeuticsBerenberg BankInitiated Coverage
3/29/2021Kymera TherapeuticsMorgan StanleyLower Price Target
11/13/2020Kymera TherapeuticsPiper SandlerInitiated Coverage
2/3/2021ImmunovantRaymond JamesLower Price Target
2/3/2021ImmunovantSVB LeerinkLower Price Target
2/2/2021ImmunovantCredit Suisse GroupDowngrade
11/13/2020ImmunovantTruistBoost Price Target
11/13/2020ImmunovantRobert W. BairdBoost Price Target
10/28/2020ImmunovantUBS GroupInitiated Coverage
10/6/2020ImmunovantLifesci CapitalReiterated Rating
10/2/2020ImmunovantCSFBInitiated Coverage
11/11/2020AlectorSmith Barney CitigroupLower Price Target
7/29/2020AlectorBarclaysLower Price Target
3/5/2020AlectorCitigroupInitiated Coverage
11/27/2019AlectorBTIG ResearchInitiated Coverage
(Data available from 5/5/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.